TITLE

Pregnancy Risk Category Information

PUB. DATE
January 2008
SOURCE
Complete Guide to Prescription & Nonprescription Drugs 2012;2008, preceding p1
SOURCE TYPE
Encyclopedia
DOC. TYPE
Article
ABSTRACT
The article offers information on the categorization of drugs falling in the pregnancy risk category, assigned by applying the definitions of the U.S. Food and Drug Administration (FDA) to the available clinical information about the drug. The drugs are assigned into following categories: A, B, C, D and X. No evidence of risk exists for drugs in the A category. Drugs in B category carry a remote risk of fetal harm. Fetal risk can't be ruled out for C category drugs.
ACCESSION #
31714877

 

Related Articles

  • Pregnancy Risk Category Information.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2007, pxviii 

    The article categorizes the drugs falling in the pregnancy risk category, assigned by applying the definitions of the U.S. Food and Drug Administration (FDA) to the available clinical information about the drug. The drugs are assigned into following categories: A, B, C, D and X. No evidence of...

  • Low Birth Weight and Preterm Births: Etiologic Fraction Attributable to Prenatal Drug Exposure. Bada, Henrietta S; Das, Abhik; Bauer, Charles R; Shankaran, Seetha; Lester, Barry M; Gard, Charlotte C; Wright, Linda L; LaGasse, Linda; Higgins, Rosemary // Journal of Perinatology;Oct2005, Vol. 25 Issue 10, p631 

    OBJECTIVES:To determine the factors that would increase the likelihood of outcomes: low birth weight (LBW), preterm births and intrauterine growth restriction (IUGR).STUDY DESIGN:Secondary data analysis from a multi-center study. Risk factors for each outcome were derived from logistic...

  • Adverse Drug Event Monitoring at the Food and Drug Administration. Ahmad, Syed Rizwanuddin // JGIM: Journal of General Internal Medicine;Jan2003, Vol. 18 Issue 1, p57 

    The Food and Drug Administration (FDA) is responsible not only for approving drugs but also for monitoring their safety after they reach the market. The complete adverse event profile of a drug is not known at the time of approval because of the small sample size, short duration, and limited...

  • Doctors, consumers and adverse reactions. Levin, Arthur Aaron // HealthFacts;Aug94, Vol. 19 Issue 183, p2 

    Reports on the reports generated by medWatch, a new Food and Drug Administration (FDA) program to encourage doctors to voluntarily report adverse effects caused by drugs and devices. Effects defined as serious; Monitoring of drugs and devices after approval as the weakest link in FDA's oversight...

  • America's real drug problem.  // HealthFacts;Jun98, Vol. 23 Issue 6, p4 

    Reports on the increasing number of fatalities associated with prescription drugs in the United States. Emergence of adverse drug reactions (ADRs) as fourth leading cause of death in the U.S.; US Food & Drug Administration's (FDA) limited resources in monitoring drug safety; Reliance of FDA on...

  • Drug- and Herb-Induced Liver Failure: A Rare Adverse Reaction to a Wide Range of Medications. Napoli, Maryann // HealthFacts;Sep2001, Vol. 26 Issue 9, p2 

    Presents information on the actions taken by the Food and Drug Administration regarding reports on drug- and herb-induced liver injury in 2001.

  • Sorbitol Loser.  // Nutrition Action Health Letter;Oct99, Vol. 26 Issue 8, p2 

    Suggests that any food with at least one gram of sorbitol should carry an informative warning. Information on the sugar alcohol sorbitol; Requirement of the United States Food and Drug Administration for food warning on sorbitol.

  • New warnings on Hismanal added by FDA.  // Drug Topics;2/16/98, Vol. 124 Issue 4, p8 

    Reports that the United States Food and Drug Administration has issued warnings on life-threatening reactions to Hismanal (astemizole) used with other drugs. Identification of drugs with which the products should not be used.

  • FDA requests voluntary recall of gamma-butyrolactone. Maudlin, Robert K. // Modern Medicine;Jan2000, Vol. 68 Issue 1, p58 

    Reports that adverse effects associated with gamma-butyrolactone (GBL) have led to the United States Food and Drug Administration's request for the recall of the dietary supplement. Brand names assumed by GBL-containing products in the market; Benefits claimed by GBL-containing products;...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics